Business Context and Reporting Period
Company: GlaxoSmithKline plc
Filing Type: Form 6-K (Report of Foreign Issuer)
Date: May 08, 2013
Reporting Period: May 2013
This filing reports a corporate action regarding the admission of shares to the Official List of the London Stock Exchange, rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of a blocklisting application and does not contain financial performance data.
Material Changes
The material change reported is the application to the Financial Conduct Authority and the London Stock Exchange for the admission of 25,000,000 ordinary shares of 25p each to the Official List. These shares are reserved under block listings for issuance pursuant to employee share schemes.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The primary contingency noted is the successful admission of the reserved shares to the Official List, after which they will rank pari passu with existing ordinary shares.
Important Facts for Investors
- Share Issuance: 25,000,000 ordinary shares are being reserved for issuance.
- Breakdown: 10,000,000 shares are for the GlaxoSmithKline Share Option Plan (Ordinary shares) and 15,000,000 are for the GlaxoSmithKline Share Option Plan (ADS).
- Share Class: The new shares will rank pari passu with existing ordinary shares upon issuance.
- Regulatory Status: An application has been made to the Financial Conduct Authority and the London Stock Exchange for admission to the Official List.